Differential roles of MMP-9 in early and late stages of dystrophic muscles in a mouse model of Duchenne muscular dystrophy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 10, 2015, Pages 2170-2182

  Shiba, Naoko ^a   Miyazaki, Daigo ^a   Yoshizawa, Takahiro ^b   Fukushima, Kazuhiro ^c   Shiba, Yuji ^a   Inaba, Yuji ^a   Imamura, Michihiro ^d   Takeda, Shin'ichi ^d   Koike, Kenichi ^a   Nakamura, Akinori ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Dystrophin; Fibrosis; MCP 1; MIP 2; MMP 9; Osteopontin

Indexed keywords

CXCL3 CHEMOKINE; GELATINASE A; GELATINASE B; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOGENIC FACTOR 5; OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR PAX3;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL INVASION; DIAPHRAGM MUSCLE; DOWN REGULATION; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; MACROPHAGE; MOUSE; MUSCLE GROWTH; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCLE STRENGTH; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; UPREGULATION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

EID: 84938691920     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.07.008     Document Type: Article

References (66)

1. Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., Kaul A., Kinnett K., McDonald C., Pandya S., Poysky J., Shapiro F., Tomezsko J., Constantin C. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9:77-93.
2. Hoffman E.P., Brown R.H., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
3. Campbell K.P., Kahl S.D. Association of dystrophin and an integral membrane glycoprotein. Nature 1989, 338:259-262.
4. Davies K.E., Nowak K.J. Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 2006, 7:762-773.
5. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
6. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
7. Sanes J.R. The basement membrane/basal lamina of skeletal muscle. J. Biol. Chem. 2003, 278:12601-12604.
8. Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol. Rev. 2004, 84:649-698.
9. Van Lint P., Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 2007, 82:1375-1381.
10. Kumar A., Bhatnagar S. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am. J. Pathol. 2010, 177:248-260.
11. Kherif S., Lafuma C., Dehaupas M., Lachkar S., Fournier J.G., Verdiere-Sahuque M., Fardeau M., Alameddine H.S. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev. Biol. 1999, 205:158-170.
12. Nakamura A., Yoshida K., Ueda H., Takeda S., Ikeda S. Up-regulation of mitogen activated protein kinases in mdx skeletal muscle following chronic treadmill exercise. Biochim. Biophys. Acta 2005, 1740:326-331.
13. Fukushima K., Nakamura A., Ueda H., Yuasa K., Yoshida K., Takeda S., Ikeda S. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet. Disord. 2007, 8:54.
14. Nadarajah V.D., van Putten M., Chaouch A., Garrood P., Straub V., Lochmuller H., Ginjaar H.B., Aartsma-Rus A.M., van Ommen G.J., den Dunnen J.T., t Hoen P.A. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 2011, 21:569-578.
15. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000, 14:2123-2133.
16. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004, 16:558-564.
17. Alameddine H.S. Matrix metalloproteinases in skeletal muscles: friends or foes?. Neurobiol. Dis. 2012, 48:508-518.
18. Miyazaki D., Nakamura A., Fukushima K., Yoshida K., Takeda S., Ikeda S. Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum. Mol. Genet. 2011, 20:1787-1799.
19. Yamada H., Saito F., Fukuta-Ohi H., Zhong D., Hase A., Arai K., Okuyama A., Maekawa R., Shimizu T., Matsumura K. Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum. Mol. Genet. 2001, 10:1563-1569.
20. Zhong D., Saito F., Saito Y., Nakamura A., Shimizu T., Matsumura K. Characterization of the protease activity that cleaves the extracellular domain of beta-dystroglycan. Biochem. Biophys. Res. Commun. 2006, 345:867-871.
21. Li H., Mittal A., Makonchuk D.Y., Bhatnagar S., Kumar A. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum. Mol. Genet. 2009, 18:2584-2598.
22. Hindi S.M., Shin J., Ogura Y., Li H., Kumar A. Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. PLoS One 2013, 8:e72121.
23. Dahiya S., Givvimani S., Bhatnagar S., Qipshidze N., Tyagi S.C., Kumar A. Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J. Immunol. 2011, 187:2723-2731.
24. Uaesoontrachoon K., Wasgewatte Wijesinghe D.K., Mackie E.J., Pagel C.N. Osteopontin deficiency delays inflammatory infiltration and the onset of muscle regeneration in a mouse model of muscle injury. Dis. Model. Mech. 2013, 6:197-205.
25. Pagel C.N., Wasgewatte Wijesinghe D.K., Taghavi Esfandouni N., Mackie E.J. Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle. J. Cell Commun. Signal. 2014, 8:95-103.
26. Vetrone S.A., Montecino-Rodriguez E., Kudryashova E., Kramerova I., Hoffman E.P., Liu S.D., Miceli M.C., Spencer M.J. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J. Clin. Investig. 2009, 119:1583-1594.
27. Porter J.D., Merriam A.P., Leahy P., Gong B., Feuerman J., Cheng G., Khanna S. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Hum. Mol. Genet. 2004, 13:257-269.
28. Hirata A., Masuda S., Tamura T., Kai K., Ojima K., Fukase A., Motoyoshi K., Kamakura K., Miyagoe-Suzuki Y., Takeda S. Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin. Am. J. Pathol. 2003, 163:203-215.
29. Hoffman E.P., Gordish-Dressman H., McLane V.D., Devaney J.M., Thompson P.D., Visich P., Gordon P.M., Pescatello L.S., Zoeller R.F., Moyna N.M., Angelopoulos T.J., Pegoraro E., Cox G.A., Clarkson P.M. Alterations in osteopontin modify muscle size in females in both humans and mice. Med. Sci. Sports Exerc. 2013, 45:1060-1068.
30. Amalfitano A., Chamberlain J.S. The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. Muscle Nerve 1996, 19:1549-1553.
31. Massa R., Silvestri G., Zeng Y.C., Martorana A., Sancesario G., Bernardi G. Muscle regeneration in mdx mice: resistance to repeated necrosis is compatible with myofiber maturity. Basic Appl. Myol. 1997, 7:387-394.
32. Nakamura A., Kobayashi M., Kuraoka M., Yuasa K., Yugeta N., Okada T., Takeda S. Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. Sci. Rep. 2013, 3:2183.
33. Carlson C.G., Rutter J., Bledsoe C., Singh R., Hoff H., Bruemmer K., Sesti J., Gatti F., Berge J., McCarthy L. A simple protocol for assessing inter-trial and inter-examiner reliability for two noninvasive measures of limb muscle strength. J. Neurosci. Methods 2010, 186:226-230.
34. Mehan R.S., Greybeck B.J., Emmons K., Byrnes W.C., Allen D.L. Matrix metalloproteinase-9 deficiency results in decreased fiber cross-sectional area and alters fiber type distribution in mouse hindlimb skeletal muscle. Cells Tissues Organs 2011, 194:510-520.
35. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol. Dis. 2008, 31:1-19.
36. Villalta S.A., Nguyen H.X., Deng B., Gotoh T., Tidball J.G. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum. Mol. Genet. 2009, 18:482-496.
37. Chazaud B., Sonnet C., Lafuste P., Bassez G., Rimaniol A.C., Poron F., Authier F.J., Dreyfus P.A., Gherardi R.K. Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. J. Cell Biol. 2003, 163:1133-1143.
38. Shireman P.K., Contreras-Shannon V., Reyes-Reyna S.M., Robinson S.C., McManus L.M. MCP-1 parallels inflammatory and regenerative responses in ischemic muscle. J. Surg. Res. 2006, 134:145-157.
39. Shireman P.K., Contreras-Shannon V., Ochoa O., Karia B.P., Michalek J.E., McManus L.M. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. J. Leukoc. Biol. 2007, 81:775-785.
40. Peterson J.M., Pizza F.X. Cytokines derived from cultured skeletal muscle cells after mechanical strain promote neutrophil chemotaxis in vitro. J. Appl. Physiol. 1985, 106(2009):130-137.
41. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 2012, 8:457-465.
42. Nico B., Mangieri D., De Luca A., Corsi P., Benagiano V., Tamma R., Annese T., Longo V., Crivellato E., Ribatti D. Nerve growth factor and its receptors TrkA and p75 are upregulated in the brain of mdx dystrophic mouse. Neuroscience 2009, 161:1057-1066.
43. Matsumura K., Zhong D., Saito F., Arai K., Adachi K., Kawai H., Higuchi I., Nishino I., Shimizu T. Proteolysis of beta-dystroglycan in muscular diseases. Neuromuscul. Disord. 2005, 15:336-341.
44. Hodgetts S., Radley H., Davies M., Grounds M.D. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul. Disord. 2006, 16:591-602.
45. Tidball J.G., Villalta S.A. Regulatory interactions between muscle and the immune system during muscle regeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298:R1173-R1187.
46. Villalta S.A., Rinaldi C., Deng B., Liu G., Fedor B., Tidball J.G. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum. Mol. Genet. 2011, 20:790-805.
47. Tidball J.G. Inflammatory processes in muscle injury and repair. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 288:R345-R353.
48. Toumi H., Best T.M. The inflammatory response: friend or enemy for muscle injury?. Br. J. Sports Med. 2003, 37:284-286.
49. Nguyen H.X., Lusis A.J., Tidball J.G. Null mutation of myeloperoxidase in mice prevents mechanical activation of neutrophil lysis of muscle cell membranes in vitro and in vivo. J. Physiol. 2005, 565:403-413.
50. Ortega-Gomez A., Perretti M., Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol. Med. 2013, 5:661-674.
51. Romanic A.M., Harrison S.M., Bao W., Burns-Kurtis C.L., Pickering S., Gu J., Grau E., Mao J., Sathe G.M., Ohlstein E.H., Yue T.L. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc. Res. 2002, 54:549-558.
52. Van den Steen P.E., Proost P., Wuyts A., Van Damme J., Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96:2673-2681.
53. Zanotti S., Gibertini S., Di Blasi C., Cappelletti C., Bernasconi P., Mantegazza R., Morandi L., Mora M. Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle regeneration and fibrosis. Histopathology 2011, 59:1215-1228.
54. Pegoraro E., Hoffman E.P., Piva L., Gavassini B.F., Cagnin S., Ermani M., Bello L., Soraru G., Pacchioni B., Bonifati M.D., Lanfranchi G., Angelini C., Kesari A., Lee I., Gordish-Dressman H., Devaney J.M., McDonald C.M. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011, 76:219-226.
55. Martinez C.O., McHale M.J., Wells J.T., Ochoa O., Michalek J.E., McManus L.M., Shireman P.K. Regulation of skeletal muscle regeneration by CCR2-activating chemokines is directly related to macrophage recruitment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 299:R832-R842.
56. Contreras-Shannon V., Ochoa O., Reyes-Reyna S.M., Sun D., Michalek J.E., Kuziel W.A., McManus L.M., Shireman P.K. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2-/- mice following ischemic injury. Am. J. Physiol. Cell Physiol. 2007, 292:C953-C967.
57. Mylona E., Jones K.A., Mills S.T., Pavlath G.K. CD44 regulates myoblast migration and differentiation. J. Cell. Physiol. 2006, 209:314-321.
58. Christoffersson G., Vagesjo E., Vandooren J., Liden M., Massena S., Reinert R.B., Brissova M., Powers A.C., Opdenakker G., Phillipson M. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012, 120:4653-4662.
59. Munoz-Canoves P., Scheele C., Pedersen B.K., Serrano A.L. Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?. FEBS J. 2013, 280:4131-4148.
60. Tomasek J.J., Halliday N.L., Updike D.L., Ahern-Moore J.S., Vu T.K., Liu R.W., Howard E.W. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J. Biol. Chem. 1997, 272:7482-7487.
61. Massova I., Kotra L.P., Fridman R., Mobashery S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998, 12:1075-1095.
62. Dahiya S., Bhatnagar S., Hindi S.M., Jiang C., Paul P.K., Kuang S., Kumar A. Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum. Mol. Genet. 2011, 20:4345-4359.
63. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
64. Manzur A.Y., Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 2008, CD003725.
65. De Paiva C.S., Corrales R.M., Villarreal A.L., Farley W.J., Li D.Q., Stern M.E., Pflugfelder S.C. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp. Eye Res. 2006, 83:526-535.
66. Mysliwiec J., Adamczyk M., Pawlowski P., Nikolajuk A., Gorska M. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves' ophthalmopathy. Endokrynol. Pol. 2007, 58:105-109.